YL202

YL202 is a novel antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 3 (HER3, also known as ErbB3). It consists of an anti-HER3 IgG1 monoclonal antibody linked via a tripeptide linker to eight molecules of YL0010014, a novel topoisomerase I inhibitor payload. The drug is designed to selectively deliver the cytotoxic payload to HER3-expressing tumor cells, thereby inhibiting tumor growth through dual mechanisms: antagonism of HER3 signaling and induction of DNA damage via topoisomerase I inhibition. YL202 is being developed for the treatment of various advanced solid tumors, including non-small cell lung cancer (NSCLC) with EGFR mutations and hormone receptor-positive/HER2-negative or triple-negative breast cancer. Clinical trials have shown encouraging efficacy and manageable safety in heavily pretreated patients[1][2][4][5][6].

Other names

anti-HER3 antibody-drug conjugate YL202anti-HER-3 antibody-drug conjugate YL202anti-HER 3 antibody-drug conjugate YL202